stella
beta
Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma — Stella
Recruiting
Back to Multiple Myeloma trials
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations
(1 site)
United States
University of California, San Francisco, San Francisco, California
View full record on ClinicalTrials.gov